Dihexa Benefits: What the Research Actually Shows

The honest summary of the table: an interesting rodent story, one supportive independent mouse study, a retracted mechanism, and nothing in people.

Dihexa is a very small modified peptide built from a fragment of angiotensin IV, itself a breakdown product of angiotensin II, the hormone most people know from blood-pressure medicine. A group at Washington State University led by Joseph Harding and John Wright found that angiotensin IV and close relatives improved memory-task performance in rats, then built a version that would survive in the body. Its chemical name is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide; the two six-carbon groups on either end protect it from enzymes and help it cross into the brain, and they give it the name "di-hexa". It is also called PNB-0408, and pharmacies label it dihexa acetate. It is not a stimulant, does not act on dopamine or noradrenaline the way attention medicines do, and is not a retail nootropic supplement.

What the research describes. The 2013 paper that introduced Dihexa, in the Journal of Pharmacology and Experimental Therapeutics, reported that Dihexa, by mouth or by injection, improved performance in the Morris water maze in two kinds of rat. The water maze is a swimming task that measures spatial memory. One group had memory impaired with scopolamine; the other was aged. These are the standard first-line models for a candidate cognitive drug, and they are the reason the compound attracted attention.

The caveat. That paper carries a 2021 expression of concern. It has not been retracted, but readers are asked to weigh it with that notice in mind.

Evidence type. Rodent.

Strength. The founding result, from the developing laboratory, with a published concern attached. It says nothing yet about people.

What the research describes. A 2021 paper in Brain Sciences, from a group separate from the developers, gave Dihexa to APP/PS1 mice. This is a strain bred to accumulate amyloid plaques and develop memory deficits. Treated mice performed better on memory testing than untreated littermates, alongside increased signalling through PI3K/Akt, a downstream route shared by several growth-factor receptors. The interpretation offered was protection of neuronal signalling rather than removal of plaque.

Evidence type. Rodent.

What it means. This is the most useful single result for Dihexa because it did not come from the people who invented it, and it points broadly the same way. It is still one study, in one mouse strain, from one laboratory. Dihexa has never been studied in people with Alzheimer's disease and is not a treatment for it. Anyone with a diagnosed or suspected dementia needs a neurologist.

What the research describes. A 2018 systematic review in Neuroscience and Biobehavioral Reviews gathered the experimental studies on angiotensin IV and the related fragment angiotensin-(1-7), and concluded that the procognitive effect in animals is consistent across models.

Evidence type. Rodent, reviewed systematically.

What it means. This review is not about Dihexa. It is the independent foundation the compound was built on: Dihexa was designed to be a longer-lasting, brain-penetrant version of that signal. It makes the starting idea credible; it does not show the finished molecule works in people.

What is claimed. Dihexa is often described as helping brain cells "form new connections." The specific finding behind that line is that it caused cultured hippocampal neurons to sprout new dendritic spines, the small structures where synapses form.

Where it came from. That finding came from a 2014 paper in the Journal of Pharmacology and Experimental Therapeutics, which also reported that the effect depended on c-Met activation. The paper received an expression of concern in 2021 and was retracted in April 2025. The developers' 2015 review in Progress in Neurobiology summarises it alongside the rodent behavioural work.

Evidence type. Cell culture, from a retracted paper.

Strength. Until it is reproduced independently, the fair description is that spine formation was reported by the developing laboratory in a dish and has not been confirmed elsewhere.

What is claimed. Many pages say Dihexa is far more potent than BDNF, the growth factor most closely tied to forming new memories.

Where it came from. The developers' own cell-culture work reported Dihexa producing more dendritic spines than BDNF at the concentrations tested. That comparison sits in the retracted work.

What it means. It is a dish comparison from a paper that can no longer be cited, and it says nothing about what either molecule does in a living human brain. Treat it as marketing shorthand.

What the research describes. Harding and Wright proposed that Dihexa binds hepatocyte growth factor (HGF) and makes it a stronger activator of its receptor, c-Met. HGF and c-Met are best known from liver regeneration and cancer biology, but the receptor is also present on hippocampal neurons, and the group argued in a 2015 review in the Journal of Alzheimer's Disease that this system drives the growth of new synaptic connections.

The retractions. The two laboratory papers carrying that claim, a 2012 paper describing Dihexa as an HGF/c-Met modifier and the 2014 paper above, were retracted in April 2025 after expressions of concern in 2021.

Strength. The mechanism may still be right. Its strongest evidence can no longer be cited, so HGF/c-Met should be read as the developing laboratory's hypothesis. The independent 2021 mouse study points to the related PI3K/Akt pathway.

What the research describes. Nothing directly. No study has measured focus, attention or "brain fog" in people given Dihexa. There is no randomised, placebo-controlled trial of Dihexa, or of any of the cognitive peptides, for attention, memory or productivity in healthy adults.

What prescribers report. Prescribers describe any subjective change in recall or focus, if it comes, emerging over weeks two to six of weekday dosing rather than on day one. Many people notice nothing in the first fortnight. These are impressions, not measurements.

What it means. Dihexa is built around recall and learning rather than attention. People who start with a specific, checkable goal, such as names at work or a language, can usually say whether anything changed; "general brain fog" is much harder to judge. Brain fog also has common, treatable causes: thyroid, B12, sleep, mood and medications. Peptides for brain fog and focus sets out what a physician looks for first.

What the research describes. A 2024 paper in the Journal of Huntington's Disease examined an angiotensin IV analogue in rats given 3-nitropropionic acid, a toxin that produces changes resembling Huntington's disease, and reported effects on some of those measures. Reviews by Wright and Harding in Frontiers in Endocrinology (2013) and in Progress in Neurobiology and the Journal of Alzheimer's Disease (2015) argue the brain's angiotensin system is a target for Alzheimer's and Parkinson's disease, with Dihexa as the lead compound.

Evidence type. One early rat study, plus reviews written by the compound's inventors.

Strength. Not evidence for any human neurological condition. Dihexa is not an approved treatment for any disease, in any country.

What the research describes. The 2013 animal paper reported Dihexa was active by mouth as well as by injection, which is unusual for a peptide and was a design goal.

What it means. That is a rat finding about absorption, not a benefit to a person. Pepti supplies Dihexa as a subcutaneous injection, because that is the route the prescribing and the pharmacy's preparation are built around, and it removes the uncertainty about how much of an oral dose reaches the bloodstream.

• That Dihexa improves memory, attention or thinking in humans. That trial has not been run.
• A human dose. The doses used are extrapolated by prescribers, not derived from a dose-finding study.
• An effect size or a timeline. Anything said about results in a set number of weeks is prescriber impression.
• That the c-Met mechanism is correct, now that the papers supporting it have been withdrawn.
• Safety in humans over any duration, including what long-term stimulation of a growth pathway active in many cancers does in people.
• Efficacy for any condition as an approved treatment. Dihexa is not approved for anything.

Dihexa acetate was placed in Category 2 of the FDA's 503A bulk substances list in 2023, the category for substances with identified safety concerns; the stated concern was the complete absence of human exposure data. In the FDA's April 2026 revisions it was moved out of Category 2, and the FDA's safety-risks page now lists it among substances whose nomination was withdrawn. The FDA has announced a Pharmacy Compounding Advisory Committee meeting before the end of February 2027 to consider dihexa acetate for the 503A bulks list. A committee vote is a recommendation, not a decision. Dihexa remains legal to prescribe and dispense as a compounded medication and is not an FDA-approved drug. Are peptides FDA approved explains the difference between not approved and not legal.

These are prescriber reports, not trial data, because there is no human safety database. The bigger question is theoretical: the proposed mechanism runs through a growth pathway that is over-active in many cancers. No study has shown Dihexa causes or speeds a tumour, and nothing rules it out, so a personal history of cancer is something your physician needs to know. The full picture is in Dihexa side effects and can peptides cause cancer.

Every price is all-in, covering medication, physician review, refill management and shipping, with no separate membership fee. Pepti is cash-pay and does not bill insurance. Vials are multi-dose solutions shipped ready to use, refrigerated with ice packs, with sterile syringes and alcohol prep pads. Refills run every 28 days, one vial per fill. Dihexa is a single vial only; it is not in any Pepti blend.

Semax has a longer record of human use than Dihexa has anywhere, as a registered medicine in Russia, and a physician cautious about Dihexa's evidence base will often suggest it first. Your physician sets your directions after reviewing your intake, and they are printed on the vial. Bloodwork is not required for any Pepti treatment. If your physician wants labs for your care, they'll ask through your account.

Dihexa cannot be bought legitimately without a prescription. Sites selling it "for research use only" are not accountable for identity, purity, sterility or concentration. The prescription route:

1. Complete a free online intake covering your history, medications and what you want help with.
2. A physician licensed in your state reviews it, usually within 24 hours.
3. If it is appropriate, a PCAB-accredited, FDA-registered US 503A compounding pharmacy prepares it to that prescription. Lot test results are published at /quality/lab-results.
4. It ships refrigerated with your directions printed on the vial.
5. Your physician stays reachable for questions and side effects.

Pepti prescribes Dihexa in every state except Oklahoma, plus DC The step-by-step page is how to get Dihexa prescribed online.